RBP-6000

DRUG8 trials

Sponsors

Indivior Inc., The University of New South Wales

Conditions

Opioid DependenceOpioid Related DisorderOpioid Related DisordersOpioid Use DisorderOpioid-related Disorders

Phase 1

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

CompletedNCT02559973

Indivior Inc.Opioid Use Disorder

Start: 2015-09-30End: 2016-03-31Updated: 2017-01-31

Single-dose, Study of RBP-6000 in Opioid Dependent Individuals

CompletedNCT02765867

Indivior Inc.Opioid Use Disorder

Start: 2010-11-30End: 2011-05-31Updated: 2016-05-09

Single Ascending Dose Study of RBP-6000

CompletedNCT03002961

Indivior Inc.Opioid Use Disorder

Start: 2012-07-31End: 2013-10-31Updated: 2016-12-26

Phase 2

Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects

CompletedNCT01738503

Indivior Inc.Opioid Related Disorder

Start: 2012-10-31End: 2014-05-31Updated: 2018-02-23

Phase 3

Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

CompletedNCT02357901

Indivior Inc.Opioid Dependence, Opioid Related Disorders

Start: 2015-01-28End: 2016-04-29Updated: 2018-02-20

Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder

CompletedNCT02510014

Indivior Inc.Opioid-related Disorders, Opioid Use Disorder

Start: 2015-07-27End: 2017-01-31Updated: 2018-03-29

Open-Label Treatment Extension Study

CompletedNCT02896296

Indivior Inc.Opioid-related Disorders, Opioid Use Disorder

Start: 2016-08-17End: 2017-08-23Updated: 2018-11-29

Community Studies of Long Acting Buprenorphine (CoLAB)

The University of New South WalesOpioid Dependence

Start: 2019-05-22End: 2021-03-30Updated: 2020-03-05

Related Papers

Treatment and recovery from opioid use disorder: The role of pain severity in individuals with moderate to severe pain.

2025-09-25

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.

2023-12-024 citations

18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.

2023-08-306 citations

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder

Frontiers in Pharmacology2022-11-1826 citations

Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings

Journal of Addiction Medicine2022-09-1612 citations

Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study.

2022-03-0910 citations

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.

2021-11-0134 citations

Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS.

2021-09-2422 citations

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study

BMJ Open2020-07-0119 citations

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study

Journal of Addiction Medicine2020-03-1350 citations

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

2019-02-18206 citations